At the time of decision-making in Western countries, including Greece Fourth dose administration of corona virus vaccine to immunocompromised individuals, Most countries in Africa and parts of Asia are looking forward to once again capturing the greatest inequality on our planet and achieving even a few volumes of the first installment.
Where the poor and his fate
Consider only the following: When almost in our country 70% of people have completed their vaccination (If two doses of the vaccine or one of the Johnson & Johnson formulations is selected), In Burundi, Central Africa, only 0.04% of the population (12,300,000 people) like us are vaccinated. At this rate, the country could vaccinate 70% of its population at தொடக்க 2111 (and in full, two hundred and eleven years) in early January!
It is once again clear that where one is born largely determines one’s future. From the estimated years that he lives on average, to whether he can access even a basic health care system, whether he works hard to secure his food and whether he can go to school.
Omigran’s complacency was not justified
Recently, there has been a resurgence not only in Greece but also in many European countries Corona virus In the coming months, it will be a bad memory due to the Omigron mutation as it spreads fast but with mild symptoms. So it can make the majority of the population sick, but without it it creates serious problems.
But no one can guarantee that a new mutation of Govit-19 will not appear in the future, which is so dangerous and equally contagious that even the worst version will not be caught by existing vaccines.
Developed in mutations in Africa
ஆக International spread If vaccines and the population of African countries were to be inaccessible to anything else, “underdeveloped” in school textbooks, then “Third World countries” (incorrectly used by the French journalist Alfred Chavez in 1952 to describe countries that were not part of the Western or Eastern Congregation in the context of the Cold War). And nowadays we refer to them as “growing” for politically correct reasons.
However, unfortunately, the gap that separates them from the Western world is the biggest and most important part of the mutations that come from these neglected countries. For example The Omigron mutation Most disturbing to us recently, it was first identified in South Africa on November 24, 2021, when the World Health Organization considered it dangerous and we first called it the “mutation of South Africa” and were baptized in Greek script. Omigron, so as not to “target” the country – a tactic followed with previous mutations.
Poor vaccination rates
According to a study by the Corporate Europe Laboratory, while vaccination rates are as high as 80% in high-income countries, only 2.3% of people in low-income countries receive a single dose, meaning that hundreds of millions of people are at risk of becoming seriously ill and ending up without even access to a hospital.
We specify that In the Democratic Republic of Congo 0.13% of the population is vaccinatedChad 0.47%, Haiti 0.63%, Guinea-Bissau 1.14%, Yemen 1.19%, Ethiopia 1.32%, South Sudan 1.59%, Madagascar 1.88%, Mali 1.95%, Niger 2.1%, Papua 2.1%, New Guinea 2.39%, Cameroon 2.4. % Uganda 2.9%, Burkina Faso 2.98%, Niger 3.77%, Malawi 3.59%, Syria 4.31%, Sierra Leone 4.69 Somalia 4.89%, Senegal, Senegal 3.85%, Senegal 36%, 56%. African Republic 6.99%, Ghana 7.28%, Gabon 7.51%, Kenya 7.69%, Solomon Islands 7.85%, Ivory Coast 7.9%, Djibouti 9.05%, Afghanistan 9.33% and Gambia 8. The 9.359%
Really sad rates, in dozens of other countries where vaccination rates are so low they are not even recorded in the statistics.
Why don’t pharmaceutical companies issue patents?
Corporate Europe Observatory considers non-issuance of vaccine patents to be the main reason for the unavailability of organic products in poor African and some Asian countries. If so, cheaper vaccines may be available from developing governments. It is generally emphasized that “a small number of pharmaceutical companies maintain control over the price and production of vaccines. Is available through this property they own. “
It continues: “Pfizer, BioNTech and Moderna are making more than $ 1,000 per second in sales of the Kovit-19 vaccine. In rich countries, other parts of the world are still waiting to access them. During the current epidemic, governments have complied with the demands of pharmaceutical companies to protect the copyright and profitability of these multinationals, rather than pursuing policies and practices that increase access to vaccines worldwide.
Despite the options, the EU has not pressured companies to do the vaccine “globally for the benefit”
There are many voices who argue that forcing pharmaceutical companies to share prescriptions for vaccines is the right thing to do.
One of the stated goals of the agreement on joint distribution of vaccines between EU member states and the Commission in mid-June 2020 is to urge pharmaceutical companies to share their intellectual property. The agreement specifically states that “the European Commission will promote the COVID-19 vaccine as a global public good. This promotion will include access to these vaccines in adequate quantities and at low cost to low- and middle-income countries. The Commission also seeks to raise questions in the pharmaceutical industry about the intellectual property sharing of how vaccines are prepared.
In practice, however, EU negotiators have made no effort to ensure that vaccines become a “global public good”. For this, pharmaceutical companies need to share vaccine technology, which will be manufactured in the required quantities Vaccine People around the world, including billions of people living in low-income countries. There are currently 1,373,486,000 people living in Africa alone.
“Industrial” production of mutations due to low vaccination
They warn that if this situation continues, the African continent could become an “industry” that will become increasingly resistant to existing defenses (i.e. vaccines and drugs). The hand does not take any significant action to provide adequate size and syringe requirements and to maintain consistent protection Vaccine patents.
Western nations do it all When they see millions of purchased vaccines expiring, they will not use them and give them to poor countries. But this obviously does not solve the problem.